Important event

Kangning Jerry Pharmaceutical-B (09966) collaborates with CSPC Pharma on the development and commercialization of JSKN003 in mainland China

Nio Inc-SW (09866) received strategic investment of 3.3 billion yuan in Nio China.

fosun pharma (02196) has obtained approval for the listing registration of its subsidiary's oxaliplatin injection.

Sunway Int'l (00058) plans to receive a cash tender offer from its controlling shareholder Fuheng Group. Trading will resume on September 30.

Guolian Securities (01456): The application for the significant asset restructuring related to the acquisition of Minsheng Securities has been accepted.

Fosun Pharma (02196): Xingsheng Xinhui has obtained approval from the National Medical Products Administration for the clinical trial of XS-04 tablets for the treatment of hematological malignancies.

Henlius (02696): The Phase III international multicenter clinical study of HLX11 for neoadjuvant treatment of HER2-positive and HR-negative early or locally advanced breast cancer has achieved its primary endpoint.

Sino Biopharm (01177): The Phase III study data of combined use of Cumarin capsules with Fluviamexin injections for the treatment of endocrine-treated HR+/HER2- advanced breast cancer stage III were announced at CSCO in 2024.

Binhai Investment (02886) and its subsidiaries plan to increase the registered capital of Sinopec's liquefied natural gas in proportion.

Chi-Med (02487): The Phase I clinical trial of CU-10101, a novel topical small molecule drug, for the treatment of atopic dermatitis has completed the first subject enrollment.

Financial report data.

Dynamic Holdings (00029) released annual performance report, with shareholders' attributable surplus of 5.354 billion Hong Kong dollars, a year-on-year increase of 80604.78%, and a final dividend of 0.5 Hong Kong cents per share.

3DG Holdings (02882) released annual performance report, with shareholders' attributable loss of 0.135 billion Hong Kong dollars, a 51% year-on-year increase.

Winfull GP (00183) released its annual performance, with shareholders' attributable loss of 0.242 billion Hong Kong dollars, a year-on-year increase of 257.85%.

Zhongzheng Intl (00943) released its annual performance, with shareholders' attributable loss of 0.699 billion Hong Kong dollars.

Transmit Ent (01326) released its annual performance, with shareholders' attributable loss of 0.351 billion Hong Kong dollars, an 87.52% increase year-on-year.

China Motor Bus (00026) released its annual performance, with a post-tax shareholders' attributable loss of 0.262 billion Hong Kong dollars, a 68.92% increase year-on-year.

For more details, please refer to the CITIC Securities website ().